
ABOUT US
RemAb Therapeutics is a spin‐off of Bellvitge Biomedical Research Institute, based in Barcelona.

PROBLEM
Antimicrobial resistance (AMR) is a growing global threat to human health and economic development.
.

PRODUCT
RA01 is novel drug product and a first line therapy for preventing nosocomial infections at ICUs.
.